IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
3
Bullish
9
Bearish
22
Neutral
15
Bullish
9
Bearish
20
Neutral
12
Bullish
0
Bearish
20
Neutral
12
Bullish
0
Bearish
20
Neutral
12
Bullish
0
Bearish
20
Neutral
12
Bullish
0
Investor Presentation
Q4 FY25
NOVYRA PHARMACHEM LIMITED (BANSTEA) is currently trading at 7.68 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Limited) is a listed Indian company historically engaged in tea cultivation and manufacturing from Darjeeling, which has amended its main object to operate three reportable segments: Pharma, Real Estate and Tea Estate following a name change effective January 2026 and corporate restructuring during 2025–26. The company reported standalone total revenue from operations of 172.61 for the quarter ended June 30, 2026, total expenses of 174.60 and a loss before tax of (1.99); statutory auditors performed a limited review and the audit report contains no matters of emphasis in the review dated August 14, 2026. Corporate governance actions in the quarter included Board approval of unaudited results on August 14, 2026 and continued adherence to Ind AS 34 interim reporting; paid-up equity share capital is reported at 633.00 with face value of Rs.10, and basic diluted EPS for the period was approximately (0.03). The company now discloses three reportable segments: Pharma, Real Estate and Tea Estate; segment reporting shows Pharma as a visible contributor in the quarter, while Real Estate and Tea Estate contributions are smaller and the consolidated profile remains loss-making at the quarterly level, highlighting early-stage diversification and execution risk. Management emphasised review of the business at the Board meeting and the statutory auditor issued a limited review report with no adverse findings; however investor presentation provides no forward revenue guidance or material capital expenditure details for the new pharma vertical, leaving strategic execution and timing unclear.
Over the past 52 weeks, NOVYRA PHARMACHEM LIMITED has traded between a low of ₹7.68 and a high of ₹16.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
NOVYRA PHARMACHEM LIMITED has a market capitalization of approximately 4.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
NOVYRA PHARMACHEM LIMITED’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -0.90 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4.86 Cr, NOVYRA PHARMACHEM LIMITED is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
NOVYRA PHARMACHEM LIMITED operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of NOVYRA PHARMACHEM LIMITED is -0.90. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Limited) is a listed Indian company historically engaged in tea cultivation and manufacturing from Darjeeling, which has amended its main object to operate three reportable segments: Pharma, Real Estate and Tea Estate following a name change effective January 2026 and corporate restructuring during 2025–26.
The company reported standalone total revenue from operations of 172.61 for the quarter ended June 30, 2026, total expenses of 174.60 and a loss before tax of (1.99); statutory auditors performed a limited review and the audit report contains no matters of emphasis in the review dated August 14, 2026.
Corporate governance actions in the quarter included Board approval of unaudited results on August 14, 2026 and continued adherence to Ind AS 34 interim reporting; paid-up equity share capital is reported at 633.00 with face value of Rs.10, and basic diluted EPS for the period was approximately (0.03).
The company now discloses three reportable segments: Pharma, Real Estate and Tea Estate; segment reporting shows Pharma as a visible contributor in the quarter, while Real Estate and Tea Estate contributions are smaller and the consolidated profile remains loss-making at the quarterly level, highlighting early-stage diversification and execution risk.
Management emphasised review of the business at the Board meeting and the statutory auditor issued a limited review report with no adverse findings; however investor presentation provides no forward revenue guidance or material capital expenditure details for the new pharma vertical, leaving strategic execution and timing unclear.
Agricultural Food & other Products
Tea & Coffee
5 Cr
Low Risk
-0.9
29.3
—
8.6
16.55
7.68
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
56.32 | 32 Cr | -6.13 | 0.57 | 0.00 | -9.79 | -2.88 | -3.98 | ||
84.83 | 27 Cr | -21.26 | 0.69 | 0.00 | -5.96 | -5.78 | -2.24 | ||
6.32 | 12 Cr | -14.78 | 0.39 | 0.00 | -1.37 | -0.31 | -1.06 | ||
35.51 | 11 Cr | 15.66 | 0.54 | 0.00 | 4.22 | 6.18 | 1.52 | ||
7.68 | 5 Cr | -0.90 | 8.55 | 0.00 | -952.75 | -952.75 | -168.32 | ||
1.25 | 5 Cr | -77.83 | 0.12 | 0.00 | 0.37 | 0.45 | -0.16 | ||
14.82 | 4 Cr | -18.54 | 0.24 | 0.00 | -1.28 | -0.97 | -1.26 | ||
| Median: 7 Co. | — | 14.82 | 11 Cr | -14.78 | 0.54 | 0.00 | -1.37 | -0.97 | -1.26 |
